HK

Hament Kumar

Active Director Director DIN 08060458
DIN 08060458 First appointment Feb 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2018
Shareholding value •••• Premium profile

About Hament Kumar

Data last updated:

Hament Kumar is a Director at Greek Pharma Private Limited (since 2018). The company operates in Pharma. Greek Pharma Private Limited reported revenue of ₹2.29 Cr (FY 2025).

DIN 08060458
Primary Designation Director
Industry Pharma
First Appointment 23 Feb 2018
Oldest Company Age 8 yrs
Largest company Greek Pharma Private Limited · ₹2.29 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Greek Pharma Private Limited U51909HR2018PTC072707
Director23 Feb 20182018₹2.29 Cr (FY 2025)Active

Board colleagues of Hament Kumar

NameDINCompanyDesignation
Anand Kumar Verma08060472Greek Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Greek Pharma Private Limited
Premium access

Shareholding and investment profile for Hament Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hament Kumar

Hament Kumar currently holds 1 directorship: Greek Pharma Private Limited (Director, since 23 Feb 2018, revenue ₹2.29 Cr (FY 2025)).

Hament Kumar was first appointed on 23 Feb 2018 as Director at Greek Pharma Private Limited.

The current boards of Hament Kumar's companies include Anand Kumar Verma (Greek Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available